Cardiac regulation by phosphoinositide 3-kinases and PTEN

Cardiovascular Research

Volumn 82, Issue 2, 2009, Pages 250-260

  Oudit, Gavin Y ^a   Penninger, Josef M ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

Author keywords

Akt; Heart failure; Hypertrophy; P13 kinase; Signalling

Indexed keywords

CYCLIC AMP; CYTOKINE RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANGIOGENESIS; CELL SURVIVAL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME STRUCTURE; FIBROBLAST; HEART; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; MECHANOTRANSDUCTION; METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HEART; HEART FAILURE; HUMANS; HYPERTROPHY; MYOCARDIUM; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 62349105876     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp014     Document Type: Review

References (116)

1. Stephens LR, Jackson TR, Hawkins PT. Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system? Biochim Biophys Acta 1993; 1179:27 75.
2. Tolias KF, Cantley LC. Pathways for phosphoinositide synthesis. Chem Phys Lipids 1999;98:69-77.
3. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602.
4. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-471.
5. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (Pl) 3-kinase family. J Cell Sd 2003;116:3037-3040.
6. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling which way to target? Trends Pharmacol Sd 2003;24:366 376.
7. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001;70:247-279.
8. DiNitto JP, Cronin TC, Lambright DG. Membrane recognition and targeting by lipid-binding domains. Sci STKE 2003;213:re16.
9. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sd USA 2008;105: 8292-8297.
10. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454:776 779.
11. Kessler A, Uphues I, Ouwens DM, Till M, Eckel J. Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase. Am J Physiol Endocrinol Metab 2001 ;280: E65-E74.
12. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki Tet al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110:737 749.
13. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 1997;89:105-114.
14. Northcott CA, Poy MN, Najjar SM, Watts SW. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res 2002;91:360-369.
15. Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki |, Sasaki T et al. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation 2003; 108: 2147-2152.
16. Macrez N, Mironneau C, Carricaburu V, Quignard JF, Babich A, Czupalla C et al. Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2 i ) channels. Circ Res 2001;89:692-699.
17. Cieslik K, Abrams CS, Wu KK. Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway. J Biol Chem 2001;276:1211-1219.
18. Chavakis E, Carmona G, Urbich C, Gottig S, Henschler R, Penninger JM et al. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res 2008;102:942 949.
19. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004; 116: 191-203.
20. Brock C, Schaefer M, Reusch HP, Czupalla C, Michalke M, Spicher K et al. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol 2003; 160: 89-99.
21. Czupalla C, Nurnberg B, Krause E. Analysis of class | phosphoinositide 3-kinase autophosphorylation sites by mass spectrometry. Rapid Commun Mass Spectrom 2003;17:690-696.
22. Leslie NR, Downes CP. PTEN: the down side of Pl 3-kinase signalling. Cell Signal 2002;14:285-295.
23. Oudit GY, Kassiri Z, Zhou J, Liu QC, Liu PP, Backx PH et al. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res 2008;78: 505-514.
24. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
25. Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sd USA 2003;100:7491 7496.
26. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. The tumoursuppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J 2004;379:301 307.
27. Campbell RB, Liu F, Ross AH. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2003;278: 33617-33620.
28. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci 2008;121:249-253.
29. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H202. J Biol Chem 2002; 277: 20336-20342.
30. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999;96:6199-6204.
31. Schwartzbauer G, Robbins J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem 2001 ;276:35786- 35793.
32. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 2002; 277:10760-10766.
33. Storz P, Toker A. 3'-phosphoinositide-dependent kinase-1 (PDK-1) in Pl 3-kinase signaling. Front Biosci 2002;7:d886-d902.
34. Mora A, Davies AM, Bertrand L, Sharif |, Budas GR, Jovanovic S et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J 2003;22:4666-4676.
35. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999; 68:965-1014.
36. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16.
37. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
38. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002;111:293-303.
39. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296: 1655-1657.
40. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sd 2003;116:1175-1186.
41. DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem 2006;281:32841-32851.
42. DeBosch B, Treskov I, Lupu TS, Weinheimer C, KovacsA, Courtois M et al. Akt1 is required for physiological cardiac growth. Circulation 2006; 113: 2097-2104.
43. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi | et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 2004;94:514-524.
44. Catalucci D, Condorelli G. Effects of Akt on cardiac myocytes: location counts. Circ Res 2006;99:339-341.
45. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol CellBiol 2002;22:2799-2809.
46. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, laccarino G et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002;99:12333- 12338.
47. Cook SA, Matsui T, Li L, Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem 2002;277:22528 22533.
48. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002;277:22896 22901.
49. Kim YK, Kim SJ, Yatani A, Huang Y, Castelli G, Vatner DE et al. Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem 2003;278:47622-47628.
50. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004;94:960-966.
51. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Sr J Pharmacol 2008; 153(Suppl. 1):S137-S153.
52. Matsuda T, Zhai P, Maejima Y, Hong C, Gao S, Tian B et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci USA 2008; 105:20900 20905.
53. AntosCL, McKinsey TA, FreyN, KutschkeW, McAnally J, Shelton JM el. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002;99:907-912.
54. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003;92:609-616.
55. Schmelzte T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253 262.
56. Harris TE, Lawrence JC Jr. TOR signaling. Sd STKE 2003;212:re15.
57. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999;253:100-109.
58. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003;107:1664-1670.
59. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70(s6 k)/p85(s6 k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMSO J 1998; 17:6649 6659.
60. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Dorfman AL et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol 2004;24: 6231-6240.
61. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res 2000;87:1172-1179.
62. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008;324:160 169.
63. Kishimoto H, Hamada K, Saunders M, Backman S, Sasaki T, Nakano T et al. Physiological functions of Pten in mouse tissues. Cell Struct Funct 2003;28:11-21.
64. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMSO J 2000; 19:2537-2548.
65. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA. Gbetagammadependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 2000;275:4693-4698.
66. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM et al. Phosphoinositide 3-kinase(p1 IOalpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 2003;100:12355-12360.
67. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004;118:375-387.
68. Pham FH, Sugden PH, Clerk A. Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. Circ Res 2000;86:1252 1258.
69. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA et al. Protective effects of exercise and phosphoinositide 3-kinase(p1 IOalpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sd USA 2007;104:612 617.
70. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001;276:38349-38352.
71. Nienaber JJ, Tachibana H, Naga Prasad SV, Esposito G, Wu D, Mao L et al. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest 2003;112:1067-1079.
72. Oudit GY, Kassiri Z. Role of PI3 kinase gamma in excitation contraction coupling and heart disease. Cardiovasc Hematol Disord Drug Targets 2007;7:295-304. 73. Houslay MD, Baillie GS, Maurice DH. cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007;100:950-966.
73. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4:566 577.
74. Kerfant BG, Zhao D, Lorenzen-Schmidt |, Wilson LS, Cai S, Chen SR et al. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res 2007; 101:400 408.
75. Jo SH, Leblais V, Wang PH, Crow MT, Xiao RP. Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation. Circ Res 2002;91:46-53.
76. Alloatti G, Levi R, Malan D, Del Sorbo L, Bosco O, Barberis L et al. Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc Res 2003;60:242-249.
77. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002;415:206-212.
78. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng YT. Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility a new transgenic model. Am J Physiol Heart Circ Physiol 2008;295:H1690-H1694.
79. von Lewinski D, Voss K, Hulsmann S, Kogler H, Pieske B. Insulin-like growth factor-1 exerts Ca2 dependent positive inotropic effects in failing human myocardium. Circ Res 2003;92:169 176.
80. Sun H, Kerfant BG, Zhao D, Trivieri MG, Oudit GY, Penninger JM et al. Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2 currents via increased P|3Kalpha/PKB signaling. Circ Res 2006; 98:1390-1397.
81. Sussman J, Stokoe D, Ossina N, Shtivelman E. Protein kinase B phosphorylates AHNAK and regulates its subcellular localization. J Cell Biol 2001 ; 154:1019-1030.
82. Hohaus A, Person V, Behlke J, Schaper J, Morano I, Haase H. The carboxyl-terminal region of ahnak provides a link between cardiac L-type Ca2 channels and the actin-based cytoskeleton. FASEB J 2002; 16:1205-1216.
83. Dedkova EN, JiX, Wang YG, Blatter LA, Lipsius SL. Signaling mechanisms that mediate nitric oxide production induced by acetylcholine exposure and withdrawal in cat atrial myocytes. Circ Res 2003;93:1233-1240.
84. Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. Neuron 2002;34:933-944.
85. Zhang Y, Wang H, Wang J, Han H, Nattel S, Wang Z. Normal function of HERG K channels expressed in HEK293 cells requires basal protein kinase B activity. FEBS Lett 2003;534:125-132.
86. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biot Chem 2003;278:39422-39427.
87. O'Neill BT, Kim J, Wende AR, Theobald HA, Tuinei J, Buchanan J et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab 2007;6:294-306.
88. Larsen M, Tremblay ML, Yamada KM. Phosphatases in cell-matrix adhesion and migration. Nat Rev Mol Cell Biol 2003;4:700 711.
89. Sugden PH. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 2003;93:1179-1192.
90. Till M, Ouwens DM, Kessler A, Eckel J. Molecular mechanisms of contraction-regulated cardiac glucose transport. Biochem J 2000; 346: 841-847.
91. Baba HA, Stypmann J, Grabellus F, Kirchhof P, Sokoll A, Schafers M et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 2003;59:390-399.
92. Shiojima |, Sato K, Izumiya Y, SchiekoferS, ItoM, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118.
93. Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 2006;20: 3347 3365.
94. Schlesinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-225.
95. Li X, Leu S, Cheong A, Zhang H, Baibakov B, Shih C et al. Akt2, phosphatidylinositol 3-kinase, and PTEN are in lipid rafts of intestinal cells: role in absorption and differentiation. Gastroenterology 2004;126:122-135.
96. Birle D, Bottini N, Williams S, Huynh H, deBelle I, Adamson E et al. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol 2002; 169:286-291.
97. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D et al. Src family proteintyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKTcascades. J Biot Chem 2003;278:40057-40066.
98. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113 1151.
99. Murphy E, Tong H, Steenbergen C. Preconditioning: is the Akt-ion in the PI3K pathway? J Mol Cell Cardiol 2003;35:1021-1025.
100. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S et al. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 2008; 103: 643-653.
101. Arab S, Konstantinov IE, Boscarino C, Cukerman E, Mori A, Li J et al. Early gene expression profiles during intraoperative myocardial ischemia-reperfusion in cardiac surgery. J Thorac Cardiovasc Surg 2007;134:74-81.
102. Mocanu MM, Bell RM, Yellon DM. PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 2002;34:661-668.
103. Kis A, Yellon DM, Baxter GF. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 2003;35:1063 1071.
104. Tong H, lmahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res 2002; 90:377 379.
105. Yamashita K, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, Anversa P et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 2001;88:609-614.
106. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 2006;72:152-162.
107. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.
108. Cai Z, Semenza GL. PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res 2005; 97:1351 -1359.
109. Siddall HK, Warrell CE, Yellon DM, Mocanu MM. Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol 2008;103:560 568.
110. Duan J, Zhang HY, Adkins SD, Ren BH, Norby FL, Zhang X et al. Impaired cardiac function and IGF-I response in myocytes from calmodulindiabetic mice: role of Akt and RhoA. Am J Physiol Endocrinol Metab 2003;284:E366-E376.
111. Taniyama Y, Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 2002;34:1241 1247.
112. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9: 1195-1201.
113. Kassiri Z, Khokha R. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost 2005;93: 212-219.
114. Curcio A, Noma T, Naga Prasad SV, Wolf MJ, Lemaire A, Perrino C et al. Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. Am J Physiol Heart Circ Physiol 2006;291: H1754-H1760.
115. Kruger M, Sachse C, Zimmermann WH, Eschenhagen T, Klede S, Linke WA. Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/AKT pathway. Circ Res 2008; 102:439 447.
116. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A et al. Angiogenesis selectively requires the p1 IOalpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453:662 666.